Posted in | News | Business | Petrochemicals

ExxonMobil Acquires Balance of Linear Low Density Polyethylene Joint Venture from Basell

Oct 5 2004

Related Stories

ExxonMobil Chemical today announced the acquisition of Basell’s 50 percent share in the Compagnie Industrielle des Polyéthylènes de Normandie (CIPEN) plant in Notre Dame de Gravenchon, France, giving it 100 percent ownership of the facility. The plant manufactures linear low density polyethylene (LLDPE) resins. The acquisition is effective as of October 1, 2004.

“Market acceptance of metallocene-based polyethylene resins continues to grow rapidly and we are committed to extending our global supply capability to meet the growing needs of our customers," said Jim Harris, senior vice president, ExxonMobil Chemical Company. "This acquisition clearly demonstrates our strong commitment to our customers and to the industry.”

For more information on polyethylene, click here.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
(Logout)
Your comment type
Submit

Sponsored Content

Editorial Highlights

The Current State of the Global Semiconductor Market

The Current State of the Global Semiconductor Market

The global semiconductor market has entered an exciting period. Demand for chip technology is both driving the industry as well as hindering it, with current chip shortages predicted to last for some time. Current trends will likely shape the future of the industry, which is set to continue to show

How are Graphene Batteries Made?

How are Graphene Batteries Made?

The primary distinction between graphene-based batteries and solid-state batteries lies in the composition of either electrode. Although the cathode is commonly changed, carbon allotropes can also be employed in fabricating anodes.

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback